Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

4.37

Margin Of Safety %

Put/Call OI Ratio

0.04

EPS Next Q Diff

-0.04

EPS Last/This Y

-0.48

EPS This/Next Y

0.3

Price

0.84

Target Price

8.5

Analyst Recom

1.25

Performance Q

-15.75

Relative Volume

0.45

Beta

1.87

Ticker: GOSS




22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-03-20GOSS1.340.030.0045469
2025-03-21GOSS1.3750.030.0845466
2025-03-24GOSS1.270.030.1144827
2025-03-25GOSS1.280.030.0045113
2025-03-26GOSS1.160.030.0245691
2025-03-27GOSS1.1650.030.0245872
2025-03-28GOSS1.170.030.0045924
2025-03-31GOSS1.0950.030.0045973
2025-04-01GOSS0.98720.030.3746435
2025-04-02GOSS0.98840.030.3246493
2025-04-03GOSS0.94630.030.1846499
2025-04-04GOSS0.820.030.5346649
2025-04-07GOSS0.850.030.1846679
2025-04-08GOSS0.78810.030.0047033
2025-04-09GOSS0.89770.030.3747062
2025-04-10GOSS0.770.030.0647235
2025-04-11GOSS0.83290.042.4547473
2025-04-14GOSS0.81340.044.6947630
2025-04-15GOSS0.83310.041.0047703
2025-04-16GOSS0.83050.040.0047744
2025-04-17GOSS0.84470.040.0048221
2025-04-18GOSS0.84250.040.0048221
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-03-20GOSS1.350.0-90.0-0.68
2025-03-21GOSS1.380.0-94.5-0.74
2025-03-24GOSS1.281.1-75.9-0.74
2025-03-25GOSS1.281.1-89.4-0.74
2025-03-26GOSS1.181.1-75.5-0.74
2025-03-27GOSS1.161.1-88.8-0.74
2025-03-28GOSS1.171.1-92.9-0.73
2025-03-31GOSS1.101.1-77.7-0.73
2025-04-01GOSS0.991.1-72.2-0.73
2025-04-02GOSS0.981.1-87.2-0.73
2025-04-03GOSS0.941.1-82.7-0.73
2025-04-04GOSS0.821.1-61.2-0.73
2025-04-07GOSS0.851.1-108.6-0.73
2025-04-08GOSS0.791.1-80.8-0.73
2025-04-09GOSS0.901.1-132.6-0.73
2025-04-10GOSS0.771.1-60.1-0.73
2025-04-11GOSS0.831.1-110.8-0.73
2025-04-14GOSS0.811.1-87.4-0.73
2025-04-15GOSS0.831.1-96.5-0.73
2025-04-16GOSS0.831.1-92.5-0.73
2025-04-17GOSS0.841.1-95.0-0.73
2025-04-18GOSS0.841.1-91.3-0.73
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-03-20GOSS0.00-3.143.06
2025-03-21GOSS0.00-3.143.06
2025-03-24GOSS0.00-7.123.06
2025-03-25GOSS0.00-7.123.06
2025-03-26GOSS0.00-7.123.14
2025-03-27GOSS0.00-7.123.14
2025-03-28GOSS0.00-7.123.14
2025-03-31GOSS0.00-7.123.14
2025-04-01GOSS0.00-7.123.14
2025-04-02GOSS0.00-7.123.14
2025-04-03GOSS0.00-7.123.14
2025-04-04GOSS0.00-7.123.14
2025-04-07GOSS0.00-7.123.14
2025-04-08GOSS0.00-7.123.14
2025-04-09GOSS0.00-7.123.14
2025-04-10GOSS0.00-7.124.37
2025-04-11GOSS0.00-7.124.37
2025-04-14GOSS0.00-7.124.37
2025-04-15GOSS0.00-7.124.37
2025-04-16GOSS0.00-7.124.37
2025-04-17GOSS0.00-7.124.37
2025-04-18GOSS0.00-7.124.37
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-0.15

Avg. EPS Est. Current Quarter

-0.19

Avg. EPS Est. Next Quarter

-0.19

Insider Transactions

Institutional Transactions

-7.12

Beta

1.87

Average Sales Estimate Current Quarter

3

Average Sales Estimate Next Quarter

4

Fair Value

Quality Score

24

Growth Score

26

Sentiment Score

53

Actual DrawDown %

95

Max Drawdown 5-Year %

-97

Target Price

8.5

P/E

Forward P/E

PEG

P/S

1.67

P/B

6.47

P/Free Cash Flow

EPS

-0.26

Average EPS Est. Cur. Y​

-0.73

EPS Next Y. (Est.)

-0.44

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-49.28

Relative Volume

0.45

Return on Equity vs Sector %

-211.7

Return on Equity vs Industry %

-198.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

-91.3
Gossamer Bio, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 144
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
stock quote shares GOSS – Gossamer Bio, Inc. Stock Price stock today
news today GOSS – Gossamer Bio, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch GOSS – Gossamer Bio, Inc. yahoo finance google finance
stock history GOSS – Gossamer Bio, Inc. invest stock market
stock prices GOSS premarket after hours
ticker GOSS fair value insiders trading